Advertisement
Advertisement
U.S. Markets close in 2 hrs 59 mins
Advertisement
Advertisement
Advertisement
Advertisement

ResMed Inc. (RMD.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
34.70+0.19 (+0.55%)
At close: 05:10PM AEDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close34.51
Open34.60
Bid34.65 x 0
Ask34.76 x 0
Day's Range34.43 - 34.79
52 Week Range27.37 - 38.41
Volume1,600,168
Avg. Volume1,151,456
Market Cap50.926B
Beta (5Y Monthly)0.42
PE Ratio (TTM)34.42
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.24 (0.69%)
Ex-Dividend DateMay 11, 2022
1y Target EstN/A
  • GlobeNewswire

    ResMed Announces Participation in the Bank of America Global Healthcare Conference

    SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a fireside chat at the Bank of America Global Healthcare Conference on Wednesday, September 14, 2022, beginning at approximately 9:05 a.m. (British Summer Time) at the Bank of America Financial Centre in London. More information about this event, including a live webcast, may be accessed by visiting http://investor.resmed.com. The webcast replay wi

  • GlobeNewswire

    ResMed Announces Participation in the 20th Annual Morgan Stanley Global Healthcare Conference

    SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on Monday, September 12, 2022, beginning at approximately 8:45 a.m. (Eastern Daylight Time) at the Sheraton New York in New York City. More information about this event, including a live webcast, may be accessed by visiting http://investor.resmed.com. The we

  • GlobeNewswire

    Over 480 Million People Estimated to Have COPD, World’s Third Deadliest Disease, ResMed Study Reports

    New prevalence figure 22–126% higher than previous estimatesPrevalence expected to reach 592 million by 2050Researchers urge global action on smoking cessation and air pollution reduction BARCELONA, Spain, Sept. 04, 2022 (GLOBE NEWSWIRE) -- Over 480 million people worldwide likely suffer from chronic obstructive pulmonary disease, or COPD, according to a late-breaking abstract led by ResMed (NYSE: RMD, ASX: RMD) presented at the European Respiratory Society Congress today.1 This figure is 22–126

Advertisement
Advertisement